DIPTHERIA, TETANUS, PERTUSSIS, HEPATITIS B, POLIOMYELITIS AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE (DTaP-HB-IPV-Hib)

Information current as at: 1 November 2026

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Vaxelis®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
sanofi-aventis Australia Pty Ltd
Condition/indication:
(therapeutic use)
    Listing requested:
    Please see PSD for more information
    Funding program:
    Please see PSD for more information
    Request authority level:
    Please see PSD for more information
    PBAC Submission type:
    New listing (–)
    Comment:
    --
    Other PBAC consideration:
    --

    Progress Details

    Submission received for:
    March 2022 PBAC meeting
    Opportunity for consumer comment:
    Open 24/11/2021 and close 27/01/2022 (see PBS Website)
    PBAC meeting:
    Held on 09/03/2022
    PBAC outcome published:
    Recommended (see PBAC Outcomes)
    Notice of intent submitted:
    Not Applicable
    Lodgement of required documentation:
    Not applicable
    Agreement to listing arrangements:
    Not applicable
    Government processes:
    Not applicable
    Medicine listed on the PBS:
    Not applicable
    Glossary

    PBAC Outcome

    PBAC Recommendation:
    Please see the Outcomes from the relevant meeting for more information
    Public Summary Document:
    PBAC Public Summary Documents – March 2022
    Case ID
    a465
    Page last updated
    20 March 2024
    Return to the Medicine Status Listing
    v.9.16